Creo Medical Limited
CREO.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | – | £0 | £0 |
| % Growth | – | – | 0.7% | – |
| Cost of Goods Sold | £0 | – | £0 | £0 |
| Gross Profit | £0 | – | £0 | £0 |
| % Margin | 45.5% | – | 47.4% | 51.7% |
| R&D Expenses | £0 | – | £0 | £0 |
| G&A Expenses | £0 | – | £0 | £0 |
| SG&A Expenses | £0 | – | £0 | £0 |
| Sales & Mktg Exp. | £0 | – | £0 | £0 |
| Other Operating Expenses | -£0 | – | £0 | -£0 |
| Operating Expenses | -£0 | – | £0 | £0 |
| Operating Income | -£0 | – | -£0 | -£0 |
| % Margin | -454.5% | – | -90.1% | -78.1% |
| Other Income/Exp. Net | £0 | – | -£0 | £0 |
| Pre-Tax Income | £0 | – | -£0 | -£0 |
| Tax Expense | £0 | – | -£0 | -£0 |
| Net Income | £0 | – | -£0 | -£0 |
| % Margin | 768.2% | – | -80.9% | -66.9% |
| EPS | 0.041 | – | -0.034 | -0.028 |
| % Growth | – | – | -21% | – |
| EPS Diluted | 0.041 | – | -0.034 | -0.028 |
| Weighted Avg Shares Out | 0 | – | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | – | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | – | £0 | £0 |
| Interest Expense | £0 | – | £0 | £0 |
| Depreciation & Amortization | £0 | – | £0 | £0 |
| EBITDA | -£0 | – | -£0 | -£0 |
| % Margin | -431.8% | – | -77.6% | -61.6% |